HHS secured more than 500,000 treatment courses of Remdesivir for American hospitals through September, according to emailed statement from agency.
- This represents 100% of Gilead’s projected production for July, 90% of production in August, 90% of production in September
- Hospitals will pay no more than approximately $3,200 per treatment course
- “Generally, patients do not pay directly for hospital-administered drugs like remdesivir; rather, for Medicare and most private insurers, the drug’s cost is incorporated into payments made by the insurer, such as Medicare paying for the drug through a diagnostic-related group”
To contact the reporter on this story: